化学
结合
抗体-药物偶联物
模式
胶水
药品
边疆
计算生物学
抗体
药物开发
药理学
组合化学
单克隆抗体
免疫学
医学
数学
社会科学
生物
历史
数学分析
社会学
复合材料
考古
材料科学
作者
Yam B. Poudel,Ruchita R. Thakore,Eugene L. Piatnitski Chekler
标识
DOI:10.1021/acs.jmedchem.4c01289
摘要
Herein, we discuss advancements in the field of a unique class of antibody-drug conjugates (ADCs) named molecular glue-antibody conjugate (MAC). ADCs traditionally employ cytotoxic agents as payloads, and this approach has been used in all approved ADCs to treat cancer. Complementary to this approach, proteolysis targeting chimera (PROTAC) degrader antibody conjugates (DACs) provide a unique opportunity to deliver these bifunctional agents to tumors by using antibodies as a delivery mechanism to overcome the bioavailability issues encountered by PROTAC payloads. Recently, a cereblon binding monovalent degrader called molecular glues has been used in new ADCs that we have coined the term molecular-glue antibody conjugates (MACs). In this article, we intend to review advancements made in the field of targeted delivery of cereblon-based molecular glue degraders.
科研通智能强力驱动
Strongly Powered by AbleSci AI